|
Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L) Bundle
Discover the true potential of Laboratorios Farmaceuticos Rovi, S.A. (0ILLL) with our advanced DCF Calculator! Adjust key assumptions, explore various scenarios, and evaluate how changes influence Laboratorios Farmaceuticos Rovi, S.A. (0ILLL) valuation – all within one convenient Excel template.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.0 | 648.7 | 817.7 | 829.5 | 763.7 | 905.1 | 1,072.6 | 1,271.2 | 1,506.4 | 1,785.3 |
| Revenue Growth, % | 0 | 54.46 | 26.06 | 1.44 | -7.93 | 18.51 | 18.51 | 18.51 | 18.51 | 18.51 |
| EBITDA | 93.3 | 204.7 | 276.6 | 238.0 | 208.2 | 259.9 | 308.0 | 365.0 | 432.5 | 512.5 |
| EBITDA, % | 22.21 | 31.56 | 33.83 | 28.69 | 27.26 | 28.71 | 28.71 | 28.71 | 28.71 | 28.71 |
| Depreciation | 19.6 | 21.4 | 22.9 | 18.5 | 28.0 | 30.2 | 35.7 | 42.4 | 50.2 | 59.5 |
| Depreciation, % | 4.67 | 3.29 | 2.8 | 2.24 | 3.67 | 3.33 | 3.33 | 3.33 | 3.33 | 3.33 |
| EBIT | 73.7 | 183.4 | 253.7 | 219.5 | 180.2 | 229.7 | 272.2 | 322.6 | 382.3 | 453.1 |
| EBIT, % | 17.55 | 28.27 | 31.03 | 26.46 | 23.59 | 25.38 | 25.38 | 25.38 | 25.38 | 25.38 |
| Total Cash | 53.2 | 99.0 | 124.9 | 25.3 | 27.4 | 90.2 | 106.9 | 126.7 | 150.2 | 178.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 84.2 | 160.1 | 184.2 | 143.3 | 129.5 | 183.7 | 217.7 | 258.0 | 305.7 | 362.3 |
| Account Receivables, % | 20.05 | 24.68 | 22.52 | 17.28 | 16.96 | 20.3 | 20.3 | 20.3 | 20.3 | 20.3 |
| Inventories | 227.2 | 245.5 | 311.9 | 338.0 | 330.0 | 387.5 | 459.2 | 544.1 | 644.9 | 764.2 |
| Inventories, % | 54.1 | 37.84 | 38.15 | 40.74 | 43.2 | 42.81 | 42.81 | 42.81 | 42.81 | 42.81 |
| Accounts Payable | 63.5 | 97.4 | 128.5 | 109.1 | 75.7 | 124.7 | 147.8 | 175.2 | 207.6 | 246.0 |
| Accounts Payable, % | 15.11 | 15.02 | 15.71 | 13.15 | 9.91 | 13.78 | 13.78 | 13.78 | 13.78 | 13.78 |
| Capital Expenditure | -39.7 | -40.9 | -51.4 | -53.8 | -59.1 | -65.7 | -77.8 | -92.2 | -109.3 | -129.5 |
| Capital Expenditure, % | -9.45 | -6.31 | -6.28 | -6.49 | -7.74 | -7.25 | -7.25 | -7.25 | -7.25 | -7.25 |
| Tax Rate, % | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 | 23.03 |
| EBITAT | 62.0 | 153.8 | 196.5 | 169.6 | 138.7 | 183.6 | 217.6 | 257.9 | 305.6 | 362.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -206.1 | 74.1 | 108.5 | 129.8 | 96.0 | 85.4 | 92.9 | 110.1 | 130.5 | 154.6 |
| WACC, % | 5.94 | 5.94 | 5.93 | 5.93 | 5.93 | 5.94 | 5.94 | 5.94 | 5.94 | 5.94 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 475.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 158 | |||||||||
| Terminal Value | 4,008 | |||||||||
| Present Terminal Value | 3,004 | |||||||||
| Enterprise Value | 3,479 | |||||||||
| Net Debt | 99 | |||||||||
| Equity Value | 3,380 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | 66.09 |
What You'll Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled financial data for Laboratorios Farmaceuticos Rovi, S.A. (0ILLL).
- Accurate Data: Comprehensive historical figures and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Instant Calculations: Quickly visualize how your input changes impact the valuation of Rovi.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Format: Organized for clear navigation and ease of use, complete with detailed instructions.
Key Features
- Comprehensive Data: Access Rovi’s historical financial reports and pre-filled projections.
- Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins to suit your analysis.
- Real-Time Results: View Rovi’s intrinsic value updating instantly as you adjust inputs.
- Insightful Visual Outputs: Dynamic dashboard charts present valuation outcomes and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Step 1: Download the prebuilt Excel template containing data for Laboratorios Farmaceuticos Rovi, S.A. (0ILLL).
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Immediately see the updated results, including the intrinsic value of Laboratorios Farmaceuticos Rovi, S.A. (0ILLL).
- Step 5: Use the outputs to make well-informed investment decisions or create comprehensive reports.
Why Choose Laboratorios Farmaceuticos Rovi, S.A. (0ILLL)?
- Save Time: Access ready-to-use tools without the hassle of starting from scratch.
- Enhance Accuracy: Dependable financial data and calculations help minimize valuation errors.
- Fully Customizable: Adjust the model to align with your specific assumptions and forecasts.
- Easy to Understand: User-friendly charts and results facilitate straightforward analysis.
- Trusted by Professionals: Created for experts who prioritize accuracy and ease of use.
Who Can Benefit from Laboratorios Farmaceuticos Rovi, S.A. (0ILLL)?
- Investors: Enhance your investment choices with a reliable assessment tool tailored for the pharmaceutical sector.
- Financial Analysts: Streamline your analysis with a customizable financial model designed for pharmaceutical valuations.
- Consultants: Efficiently modify the available templates for impactful client presentations or detailed reports.
- Pharmaceutical Enthusiasts: Expand your knowledge of industry-specific valuation methods through practical examples.
- Educators and Students: Utilize this resource as a hands-on learning aid in pharmaceutical finance courses.
Contents of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Laboratorios Farmaceuticos Rovi, S.A. (0ILLL), encompassing revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), including variables such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models displaying intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate thorough analysis.
- Key Ratios: A collection of profitability, leverage, and efficiency ratios specific to Laboratorios Farmaceuticos Rovi, S.A. (0ILLL).
- Dashboard and Charts: Visual representation of valuation outputs and assumptions for easier analysis of results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.